

# Theodora Hatziioannou

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6170729/theodora-hatziioannou-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68

papers

7,870

citations

32

h-index

79

g-index

79

ext. papers

11,951

ext. citations

24.9

avg, IF

6.32

L-index

#	Paper	IF	Citations
68	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , <b>2020</b> , 584, 437-442	50.4	1167
67	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , <b>2020</b> , 9,	8.9	784
66	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , <b>2021</b> , 592, 616-622	50.4	730
65	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , <b>2021</b> , 591, 639-644	50.4	652
64	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , <b>2020</b> , 182, 828-842.e16	56.2	485
63	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 2212-2218	59.2	347
62	Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. <i>Cell Host and Microbe</i> , <b>2009</b> , 6, 409-21	23.4	339
61	MX2 is an interferon-induced inhibitor of HIV-1 infection. <i>Nature</i> , <b>2013</b> , 502, 563-6	50.4	337
60	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <i>Journal of Experimental Medicine</i> , <b>2020</b> , 217,	16.6	289
59	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , <b>2021</b> , 595, 426-431	50.4	247
58	Animal models for HIV/AIDS research. <i>Nature Reviews Microbiology</i> , <b>2012</b> , 10, 852-67	22.2	208
57	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	178
56	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	171
55	Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 3563-8	11.5	159
54	Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 389-398	7	136
53	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E3413-22	11.5	132
52	A macaque model of HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 4425-9	11.5	124

51	Generation of simian-tropic HIV-1 by restriction factor evasion. <i>Science</i> , <b>2006</b> , 314, 95	33.3	123
50	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , <b>2021</b> , 12, 4196	17.4	106
49	Plasma Neutralization of the SARS-CoV-2 Omicron Variant.. <i>New England Journal of Medicine</i> , <b>2021</b> ,	59.2	93
48	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , <b>2021</b> , 54, 1853-1868.e7	32.3	83
47	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , <b>2021</b> ,	50.4	69
46	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. <i>Nature</i> , <b>2021</b> ,	50.4	65
45	HIV-1-induced AIDS in monkeys. <i>Science</i> , <b>2014</b> , 344, 1401-5	33.3	61
44	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants <b>2021</b> ,		54
43	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , <b>2021</b> , 595, 278-282	50.4	49
42	Evolution of Antibody Immunity to SARS-CoV-2 <b>2021</b> ,		43
41	Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. <i>Cell Host and Microbe</i> , <b>2014</b> , 16, 412-8	23.4	41
40	Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents <b>2020</b> ,		37
39	Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, e1208-e1211	11.6	37
38	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. <i>Nature</i> , <b>2021</b> , 593, 424-428	50.4	36
37	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants <b>2020</b> ,		32
36	Plasma neutralization properties of the SARS-CoV-2 Omicron variant. <b>2021</b> ,		31
35	Author response: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants <b>2020</b> ,		31
34	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies <b>2020</b> ,		30

33	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients <b>2020</b> ,		30
32	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. <i>Cell Reports</i> , <b>2021</b> , 36, 109760	10.6	29
31	Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies <b>2021</b> ,		27
30	Assisted evolution enables HIV-1 to overcome a high TRIM5 $\alpha$ -imposed genetic barrier to rhesus macaque tropism. <i>PLoS Pathogens</i> , <b>2013</b> , 9, e1003667	7.6	24
29	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies <b>2021</b> ,		24
28	Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection <b>2020</b> ,		21
27	A single gp120 residue can affect HIV-1 tropism in macaques. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006572	7.6	20
26	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year <b>2021</b> ,		19
25	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro <b>2020</b> ,		15
24	Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100164	18	14
23	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. <i>Nature</i> , <b>2022</b> ,	50.4	14
22	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies <b>2021</b> ,		13
21	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. <i>Nature Immunology</i> , <b>2021</b> , 22, 1503-1514	19.1	12
20	Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection <b>2020</b> ,		12
19	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.. <i>Immunity</i> , <b>2022</b> ,	32.3	10
18	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1007632	7.6	9
17	Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants <b>2021</b> ,		8
16	Replication and single-cycle delivery of SARS-CoV-2 replicons. <i>Science</i> , <b>2021</b> , 374, 1099-1106	33.3	7

15	Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination		7
14	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009688	7.6	7
13	High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies		7
12	Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 10504-10509	11.5	6
11	Flexibility in Nucleic Acid Binding Is Central to APOBEC3H Antiviral Activity. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	5
10	Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection. <i>ELife</i> , <b>2019</b> , 8,	8.9	4
9	Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2 <b>2021</b> ,		4
8	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. <i>ELife</i> , <b>2021</b> , 10,	8.9	3
7	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. <b>2022</b> ,		3
6	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity <b>2021</b> ,		2
5	Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease <b>2021</b> ,		2
4	Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. <b>2022</b> ,		1
3	A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques <b>2020</b> ,		1
2	A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques <b>2021</b> ,		1
1	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland.. <i>Journal of Clinical Virology Plus</i> , <b>2021</b> , 1, 100028		